These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27863409)

  • 1. Integrating mechanisms of response and resistance against the tubulin binding agent Eribulin in preclinical models of osteosarcoma.
    Sampson VB; Vetter NS; Zhang W; Patil PU; Mason RW; George E; Gorlick R; Kolb EA
    Oncotarget; 2016 Dec; 7(52):86594-86607. PubMed ID: 27863409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium.
    Gill J; Zhang W; Zhang Z; Roth M; Harrison DJ; Rowshan S; Erickson S; Gatto G; Kurmasheva R; Houghton P; Teicher B; Smith MA; Kolb EA; Gorlick R
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28606. PubMed ID: 32706456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis.
    Vetter NS; Kolb EA; Mills CC; Sampson VB
    Mol Cancer Res; 2017 Jul; 15(7):953-964. PubMed ID: 28275089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group.
    Isakoff MS; Goldsby R; Villaluna D; Krailo MD; Hingorani P; Collier A; Morris CD; Kolb EA; Doski JJ; Womer RB; Gorlick R; Janeway KA
    Pediatr Blood Cancer; 2019 Feb; 66(2):e27524. PubMed ID: 30378256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eribulin: rediscovering tubulin as an anticancer target.
    Jimeno A
    Clin Cancer Res; 2009 Jun; 15(12):3903-5. PubMed ID: 19509144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program.
    Kolb EA; Gorlick R; Reynolds CP; Kang MH; Carol H; Lock R; Keir ST; Maris JM; Billups CA; Desjardins C; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2013 Aug; 60(8):1325-32. PubMed ID: 23553917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.
    Helfrich BA; Gao D; Bunn PA
    Lung Cancer; 2018 Apr; 118():148-154. PubMed ID: 29571994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
    Stehle A; Hugle M; Fulda S
    Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eribulin Inhibits Osteosarcoma in a Clinically-accurate Bone-tumor-insertion PDOX Mouse Model.
    Wu NF; Yamamoto J; Aoki Y; Bouvet M; Hoffman RM
    Anticancer Res; 2021 Apr; 41(4):1779-1784. PubMed ID: 33813382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class III
    Yahiro K; Matsumoto Y; Fukushi JI; Kawaguchi KI; Endo M; Setsu N; IIda K; Fukushima S; Nakagawa M; Kimura A; Oda Y; Nakashima Y
    Anal Cell Pathol (Amst); 2018; 2018():8987568. PubMed ID: 30034996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
    Cortes J; Montero AJ; Glück S
    Cancer Treat Rev; 2012 Apr; 38(2):143-51. PubMed ID: 21550727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
    Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
    Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation.
    Alday PH; Correia JJ
    Biochemistry; 2009 Aug; 48(33):7927-38. PubMed ID: 19586046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin.
    Laughney AM; Kim E; Sprachman MM; Miller MA; Kohler RH; Yang KS; Orth JD; Mitchison TJ; Weissleder R
    Sci Transl Med; 2014 Nov; 6(261):261ra152. PubMed ID: 25378644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eribulin mesylate for the treatment of late-stage breast cancer.
    Gourmelon C; Frenel JS; Campone M
    Expert Opin Pharmacother; 2011 Dec; 12(18):2883-90. PubMed ID: 22087618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma.
    Currier AW; Kolb EA; Gorlick RG; Roth ME; Gopalakrishnan V; Sampson VB
    Sci Rep; 2019 Apr; 9(1):6161. PubMed ID: 30992462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A transposon screen identifies enhancement of NF-κB pathway as a mechanism of resistance to eribulin.
    Teng X; Hayashida T; Murata T; Nagayama A; Seki T; Takahashi M; Kitagawa Y
    Breast Cancer; 2021 Jul; 28(4):884-895. PubMed ID: 33616862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer.
    Kashiwagi S; Fukushima W; Asano Y; Goto W; Takada K; Noda S; Takashima T; Onoda N; Ohsawa M; Hirakawa K; Ohira M
    BMC Cancer; 2017 Aug; 17(1):604. PubMed ID: 28859615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.
    Ates O; Babacan T; Kertmen N; Sarici F; Cenoli A; Akin S; Karakas Y; Kilickap S; Ozisik Y; Sever AR; Aksoy S; Altundag K
    J BUON; 2016; 21(2):375-81. PubMed ID: 27273947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma.
    Kawano S; Asano M; Adachi Y; Matsui J
    Anticancer Res; 2016 Apr; 36(4):1553-61. PubMed ID: 27069131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.